Reliefband Technologies

Executive Summary

Reliefband Technologies is a private San Diego-based company that develops and markets FDA-cleared, drug-free wearable neuromodulation devices for the prevention and treatment of nausea and vomiting. Founded in 1999, the company's flagship product, the Reliefband, uses targeted electrical stimulation of the median nerve to alleviate symptoms associated with motion sickness, morning sickness, chemotherapy, and as an adjunct to antiemetics post-surgery. With a strong regulatory foundation and a differentiated non-pharmacological approach, Reliefband addresses a significant unmet need in the nausea management market, which spans travel, pregnancy, oncology, and surgical recovery. The company's device offers a side-effect-free alternative to traditional medications, positioning it well for adoption among consumers and healthcare providers seeking drug-free options. While the company is private and does not disclose financials, its long history and growing consumer awareness suggest a stable market presence. Key growth drivers include expanding clinical evidence, increasing retail distribution, and potential label expansions for additional indications. Overall, Reliefband operates in a niche but growing segment of digital health and medical devices, with a clear value proposition in combating nausea without drowsiness or side effects.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for postoperative nausea and vomiting (PONV) as a standalone indication70% success
• Q4 2026Major retail or healthcare partnership for expanded distribution50% success
• Q1 2027Positive results from ongoing clinical trial in chemotherapy-induced nausea60% success